ASX:CP1

CannPal Animal Therapeutics (CP1) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CP1 stock logo

About CannPal Animal Therapeutics Stock (ASX:CP1)

CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia.

CP1 Stock News Headlines

How do animals grow?
Experimenting on animals
The Long-Awaited End of America Update
A 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.
Weird Animals
The animals that could be dreaming
How animals reproduce
Elanco Animal Health (NYSE: ELAN)
The Long-Awaited End of America Update
A 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.
Animal attacks
The ethics of speciesism
Talking Animals
Animals
Animal Abuse
'Forever chemicals' found in animals around the world
See More Headlines
Receive CP1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CannPal Animal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$802,623.00
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Layton Patrick Mills
    Founder, MD & Director
  • Dr. Margaret Curtis
    Head of Clinical Devel. and R&D
  • Mr. Baden Maxwell Bowen
    CFO & Company Sec.
  • Dr. Rayson Tan
    Chief Scientific Officer & Member of Advisory Board

This page (ASX:CP1) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners